Anzeige
Mehr »
Mittwoch, 01.10.2025 - Börsentäglich über 12.000 News
Globaler Gamechanger: CiTech expandiert in Europa - neue Chancen für Investoren!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1JKVH | ISIN: IE00B56GVS15 | Ticker-Symbol: 8AK
Tradegate
30.09.25 | 18:42
25,400 Euro
-0,78 % -0,200
1-Jahres-Chart
ALKERMES PLC Chart 1 Jahr
5-Tage-Chart
ALKERMES PLC 5-Tage-Chart
RealtimeGeldBriefZeit
25,80026,20018:23
25,80025,80018:14

Aktuelle News zur ALKERMES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrAlkermes upgraded at RBC Capital Markets ahead of key catalyst1
Fr9 Analysts Assess Alkermes: What You Need To Know1
FrAlkermes stock rating upgraded by RBC Capital on narcolepsy drug potential2
12.09.Alkermes Names Joshua Reed Chief Financial Officer3
12.09.Alkermes Appoints Joshua Reed As CFO1
12.09.Alkermes appoints Joshua Reed as new CFO effective Monday1
12.09.Alkermes appoints new CFO2
12.09.Alkermes plc: Alkermes Appoints Joshua Reed as Chief Financial Officer252DUBLIN, Sept. 12, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) is pleased to announce the appointment of Joshua Reed as Chief Financial Officer (CFO), effective Monday, Sept. 15, 2025....
► Artikel lesen
ALKERMES Aktie jetzt für 0€ handeln
11.09.Alkermes plc: Alkermes Announces Launch of 8th Annual Alkermes Pathways Research Awards Program254- Competitive Grant Program to Offer Individual Grants of Up to $100,000 per Project - - Areas of Interest Expanded to Include Sleep and Circadian Disturbances Associated With Bipolar...
► Artikel lesen
09.09.Takeda Is Waking Up the Narcolepsy Market With First-in-Class Drug, But Alkermes Is on Its Heels7
08.09.Alkermes plc. - 8-K, Current Report-
08.09.Alkermes stock maintains Buy rating at Stifel following sleep disorder data1
08.09.Takeda, Alkermes lift lid on data for rival narcolepsy hopefuls as race to market heats up11
08.09.Alkermes reports positive phase 2 results for narcolepsy drug3
08.09.Alkermes plc: Alkermes Presents Detailed Positive Results from Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at World Sleep Congress 2025305- First Orexin 2 Receptor Agonist to Demonstrate Clinically Meaningful and Statistically Significant Impact on Wakefulness, Cognition and Fatigue with Once-Daily Dosing Across a Range of...
► Artikel lesen
03.09.Deep Dive Into Alkermes Stock: Analyst Perspectives (7 Ratings)1
25.08.Alkermes plc: Alkermes to Present Detailed Positive Results From Vibrance-1 Phase 2 Study Evaluating Alixorexton in Patients With Narcolepsy Type 1 at World Sleep 2025241- Results From Vibrance-1 to Be Shared in Three Oral Presentations, Including Primary and Secondary Efficacy and Safety Measures, and Exploratory Patient-Reported Outcomes Related to Disease...
► Artikel lesen
21.08.Alkermes übertrifft Prognosen für Q2 2025 - Aktie legt zu1
18.08.Piper Sandler reiterates Overweight rating on Alkermes stock at $383
08.08.BlackRock stockt Anteil an Alkermes auf 17 % auf5
Weiter >>
95 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1